Intellia Therapeutics, Inc. (LON:0JBU)
London
· Delayed Price · Currency is GBP · Price in USD 7.16
+0.22 (3.17%)
At close: Apr 17, 2025
Intellia Therapeutics Revenue
In the year 2024, Intellia Therapeutics had annual revenue of $57.88M USD with 59.55% growth. Intellia Therapeutics had revenue of $12.87M in the quarter ending December 31, 2024, a decrease of -771.57%.
Revenue
$57.88M
Revenue Growth
+59.55%
P/S Ratio
13.64
Revenue / Employee
$143.62K
Employees
403
Market Cap
630.50M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |
Intellia Therapeutics News
- 9 days ago - Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA - GlobeNewsWire
- 10 days ago - Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA - Accesswire
- 10 days ago - INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA - PRNewsWire
- 10 days ago - NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewsWire
- 10 days ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLA - Accesswire
- 10 days ago - NTLA DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA - Accesswire
- 10 days ago - NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
- 10 days ago - Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) Shareholders - Accesswire